What's in FHI 360's pipeline?

FHI 360 has 19 drugs in our index: 9 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 8 in Phase 1.

Which companies overlap with FHI 360's portfolio?

Top competitors by shared drug class: Organon and Co, HRA Pharma, Italfarmaco, Helsinki University Central Hospital, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fhi-360.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

FHI 360 — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FHI 360 pipeline: 9 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 2 Phase 3 0 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Implanon®	Implanon®	marketed	Progestin-only contraceptive	Progesterone receptor	Contraception
DMPA	DMPA	marketed			Other
Oral contraceptives--ethinyl estradiol, levonorgestrel	Oral contraceptives--ethinyl estradiol, levonorgestrel	marketed
Sayana Press	Sayana Press	marketed
LNG	LNG	marketed	Progestin (synthetic)	Progesterone receptor	Contraception
ETHINYL ESTRADIOL AND LEVOGESTREL	ETHINYL ESTRADIOL AND LEVOGESTREL	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor	Contraception / Reproductive Health
ParaGard®	ParaGard®	marketed	Intrauterine contraceptive device (copper IUD)	Copper ion-mediated spermicidal and anti-implantation effects	Contraception / Reproductive Health
oral contraceptives	oral contraceptives	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor	Contraception / Reproductive Health
Mirena®	Mirena®	marketed
ParaGard® TCu380A	ParaGard® TCu380A	phase 3	Intrauterine contraceptive device (copper-based)		Contraception
Mona Lisa® NT Cu380 Mini	Mona Lisa® NT Cu380 Mini	phase 3	Intrauterine device (IUD), copper-based contraceptive		Contraception / Reproductive Health

Therapeutic area mix

Contraception / Reproductive Health · 4
Contraception · 3
Other · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Organon and Co · 2 shared drug classes
HRA Pharma · 1 shared drug class
Italfarmaco · 1 shared drug class
Helsinki University Central Hospital · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
IVI Madrid · 1 shared drug class
Hansoh BioMedical R&D Company · 1 shared drug class
Federico II University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for FHI 360:

Cite this brief

Drug Landscape (2026). FHI 360 — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fhi-360. Accessed 2026-06-10.